US FOP prevalence higher than expected

The prevalence of fibrodysplasia ossificans progressiva (FOP) in the US is higher than previously believed, according to research published in the Orphanet Journal of Rare Diseases.
Anecdotal evidence supports further study of imatinib in children with FOP

Children treated for fibrodysplasia ossificans progressiva (FOP) with imatinib in an off-on-off-on (O4) regimen have fewer flare-ups, decreased swelling, and improved function when on versus off treatment, US researchers report.